Hameroff S R, Weiss J L, Lerman J C, Cork R C, Watts K S, Crago B R, Neuman C P, Womble J R, Davis T P
J Clin Psychiatry. 1984 Mar;45(3 Pt 2):47-53.
Sixty patients with chronic pain of the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores, Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.
对60例伴有临床抑郁症的慢性腰背痛或颈椎病患者进行了一项为期6周的多塞平与安慰剂随机双盲对照研究。与安慰剂组或基线值相比,多塞平治疗组在汉密尔顿抑郁评分、总体评估量表评分、疼痛严重程度、疼痛感受时间百分比以及疼痛对活动、睡眠和肌肉紧张的影响方面均有显著改善。治疗1周后观察到一些改善;最大改善出现在6周时,此时多塞平平均剂量约为200mg/天,血浆多塞平和去甲多塞平平均为80ng/ml。未观察到明显有害影响。血浆β-内啡肽和脑啡肽样活性与基线相比均无显著差异。这些数据表明,多塞平是治疗慢性疼痛和抑郁症患者的一种有效药物。